The global pulmonary embolism drugs market is estimated to grow at a robust CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing prevalence of pulmonary embolism. This is a condition, where a blood clot occurs in the lungs, which often is formed in other body parts and moves to the lungs through bloodstream. This limits the flow of blood to the lungs, which reduces the flow of oxygen in the body, and increases blood pressure. Pulmonary embolism drugs are used to dissolve the clots or inhibit their formation. Patients undergoing chemotherapy, or people with family history of this disease are at most risk, which is estimated to boost the demand for the drugs. Increasing patient pool of cancer is estimated to fuel the growth of the market. According to the World Health Organization, cancer caused nearly 10 million deaths in 2020. Moreover, increasing government investment to improve the public healthcare system in developing and developed countries, is further anticipated to boost the market growth.
The market is segmented by drug class into thrombolytics, heparins, thrombin inhibitors, and others out of which, the heparins segment is anticipated to hold the largest share in the global pulmonary embolism drugs market over the forecast period owing to the anticoagulant properties of heparins, that are used to dissolve the blood clot. On the basis of distribution channel, the hospital pharmacies segment is anticipated to garner the highest market revenue over the forecast period, owing to the easy accessibility of drugs to the patients admitted in hospitals.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years. CLICK TO DOWNLOAD SAMPLE REPORT
On the basis of geographical analysis, the global pulmonary embolism drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America region is estimated to witness noteworthy growth over the forecast period on the back of high healthcare expenditure in the region. According to a report by the World Health Organization (WHO), as of 2018, the per capita healthcare expenditure of North America valued USD 10,050.279. Moreover, presence of major pharmaceutical companies in the region is estimated to boost the market growth.
The market in the Asia Pacific region is estimated to gain significant share in the market over the forecast period, owing to the high prevalence of cancer in the region, along with high geriatric population, both of which are a major cause for pulmonary embolism.
The global pulmonary embolism drugs market is further classified on the basis of region as follows:
Our in-depth analysis of the global pulmonary embolism drugs market includes the following segments:
FREQUENTLY ASKED QUESTIONS
Increasing prevalence of pulmonary embolism and deadly nature of this disease are estimated to boost the market growth.
The market is anticipated to attain a robust CAGR over the forecast period, i.e., 2022 – 2030.
Side effects of the drugs are estimated to hamper the market growth.
the market in the North America region is estimated to provide most growth opportunities over the forecast period, owing to the presence of major pharmaceutical companies in the region.
The major players in the market are Novartis AG, Pfizer Inc., Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by drug class, distribution channel, and by region.
The heparins segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization